Over $461K Grant toward Enzyme Replacement Therapy with TEGA Therapeutics
TEGA Therapeutics, Inc. has been awarded a Phase I Small Business and Innovative Research (SBIR)…
-
-
Gelb Laboratory Publishes Third GM1 Newborn Screening Paper
Cure GM1 provided seed funding for, and families from the GM1 community provided dried blood…
-
2022 Cure GM1 Impact Report – Impact in 2022 and Beyond
Our summary of impact in 2022 is now available to read. After some time reflecting,…
-
The Voice of the Patient Report from the GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD)
You can now download and read the touching and impactful summary of input from GM1…
-
About the GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting with FDA
The GM1 Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) was held on Friday, October 14 as…
-
Cure GM1 Caregiver Preferences Study has been published
Our Caregiver Preferences study, The caregivers’ assessments of symptom impact and most important symptoms to…
-
Cure GM1 Foundation and TEGA Therapeutics Establish Collaboration to Develop GM1 Gangliosidosis Therapy
TEGA Cure GM1 Collaboration PDF TEGA WORLD Pres 2023
-
Two New AAV Gene Therapy Clinical Trials for Infantile and Late Infantile GM1 to Begin in Q1/Q2 2021
Cure GM1 is pleased to share the tremendous news that both Passage Bio and Lysogene have received regulatory approvals…
-
A Newborn Screening Assay for GM1 Gangliosidosis, Gelb Laboratory, University of Washington
Tandem Mass Spectrometry Assay of Beta-Galactosidase for Multiplex Newborn Screening of GM1 Gangliosidosis Michael H….